Summary of I-Mab (IMAB) Conference Call - June 17, 2025 Company Overview - **Company**: I-Mab (IMAB) - **Focus**: Development of innovative therapies for cancer, particularly targeting Claudin 18.2 in gastric cancer - **Current Status**: Transitioned to a capital-efficient model with a focus on the US market, following a divestiture of operations in China [6][12] Clinical Pipeline - **Key Asset**: Giva (Claudin 18.2 bispecific antibody) - **Clinical Stage**: Three clinical stage assets, with Giva being the primary focus [7][8] - **Upcoming Presentation**: Mini oral presentation scheduled for ESMO GI on July 2, 2025 [2][85] Core Points and Arguments - **Giva's Mechanism**: Giva is designed to enhance the standard of care for frontline gastric cancer without altering existing treatments [8][10] - **Efficacy Data**: - Monotherapy showed an Objective Response Rate (ORR) of 18% in heavily treated populations [9] - Combination studies with standard care (nivo chemo) demonstrated promising ORR and safety profiles [10][11] - **Market Opportunity**: - Addressable market for frontline Claudin 18.2 positive patients estimated at $12 billion in the US, EU, and Japan [11] - Gastric cancer is a significant unmet medical need with a low five-year survival rate of 7% for metastatic cases [10][11] Safety and Tolerability - **Safety Profile**: Giva demonstrated a favorable safety profile with minimal toxicity compared to other treatments [24][36] - **Comparison with Competitors**: Giva's grade 3 and above treatment-related adverse events were reported at 33%, significantly lower than competitors [41][42] Differentiation from Competitors - **Broad Eligibility**: Giva targets a wider range of Claudin 18.2 positive patients with a cutoff of 1% expression, unlike competitors with higher thresholds [31][39] - **Combination Potential**: Giva can be added to existing regimens without modifying standard care, making it suitable for frontline therapy [35][36] Future Development Strategy - **Focus on Gastric Cancer**: Commitment to developing Giva in frontline metastatic gastric cancer, with potential exploration in locally advanced settings and other GI cancers [55][75] - **Exploration of Other Tumor Types**: Interest in testing Giva in pancreatic and biliary tract cancers due to high Claudin 18.2 expression [55][75] Key Takeaways for Investors - **Upcoming Data**: Investors should look for data from the ESMO GI presentation, particularly regarding safety, efficacy, and the potential for Giva to improve patient outcomes [64][66] - **Long-term Potential**: Giva's unique properties and promising early data position it well for future success in treating gastric cancer and potentially other malignancies [84][85] Conclusion - I-Mab is poised for significant developments with Giva, focusing on addressing unmet needs in gastric cancer while maintaining a strong safety profile and broad eligibility for patients. The upcoming ESMO GI presentation is anticipated to provide critical data that could influence future investment and development strategies [82][84]